Cerity Partners LLC Makes New Investment in Kronos Bio, Inc. (NASDAQ:KRON)

Cerity Partners LLC acquired a new position in shares of Kronos Bio, Inc. (NASDAQ:KRON) during the 4th quarter, Holdings Channel reports. The fund acquired 410,796 shares of the company’s stock, valued at approximately $513,000.

Separately, Acadian Asset Management LLC increased its stake in Kronos Bio by 6.4% during the third quarter. Acadian Asset Management LLC now owns 614,945 shares of the company’s stock worth $798,000 after acquiring an additional 36,909 shares during the last quarter. Institutional investors own 64.09% of the company’s stock.

Kronos Bio Stock Performance

KRON opened at $0.96 on Thursday. The stock has a market cap of $57.70 million, a price-to-earnings ratio of -0.49 and a beta of 1.82. The stock’s 50 day moving average price is $1.15 and its 200-day moving average price is $1.12. Kronos Bio, Inc. has a one year low of $0.73 and a one year high of $2.29.

Kronos Bio (NASDAQ:KRON) last released its earnings results on Thursday, March 21st. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.08. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $1.50 million. Kronos Bio had a negative return on equity of 58.79% and a negative net margin of 1,791.87%. As a group, analysts predict that Kronos Bio, Inc. will post -1.74 earnings per share for the current fiscal year.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.